The serendipitous finding of ceritinib as one of the most cytotoxic compounds to KKU-M213 in RTKis’ screening led us to further our study of ceritinib to clarify and reaffirm its cytotoxicity, ALK expression and mutation status, the mechanisms of cell death, and the associated signaling pathways in CCA. This evidence concerns the gene ALK and cholangiocarcinoma.